Microdacyn leads the way in evidence-based care.
Super-oxidised solutions have some of the strongest evidence available that their use within a comprehensive treatment regime results in more effective infection control, faster healing rates, reduced time to wound healing all with unrivalled compatibility and tolerance.
If you practice evidence-based care,
welcome to Microdacyn
This page contains summaries and collections of the most relevant and up to date clinical support, guidelines and expert recommendations for Microdacyn as the leading surgical and wound management solution.
In early 2018, Kramer et al published an updated consensus on wound antisepsis in the journal of skin pharmacology and physiology
The article independently collected all the quality clinical evidence produced by a PubMed literature search and tabulated the outcomes for various wound and surgical preparations including super-oxidised solutions.
Below is the extract data for Microdacyn where it was proven superior in wound healing or infection control (or both) in all trials against all comparators.
Summary: eight (8) controlled trials were quoted, six (6) were against Povidone-Iodine in wounds, one (1) was against saline in wounds and another one (1) was against saline in surgical irrigation of the peritoneum.
Additionally, the consensus included one retrospective cohort study against silver (Ag) in burn wounds.
Microdacyn significantly improved wound healing rates in all wound trials and significantly improved surgical recovery measures in the irrigation RCT
Click To Download in Full
Microdacyn is the 1st choice antiseptic compound for decontaminating acute and chronic wounds
If This Isn't Enough To Change Your Evidence-Based Practice, Nothing Will
Prevention is always better than treatment, however, in wound care that has always been a difficult task as antiseptic use to manage infection has not been without consequence.
Each category will guide you to a clinical example where Microdacyn is proven to excel against the current standard of treatment
Traditionally antiseptics have been high concentration active solutions that can cause harm to the delicate cells involved in wound healing that cause pain or allergy on application. Not Microdacyn.
The international Wound Infection Institutes (IWII) 2016 clinical practice guidelines clearly explain that lower-concentration products are less likely to cause harm to wound healing and are preffered.
In following with guideline recommendations, Microdacyn would be recommended ahead of its higher concentration comparators first line in all wound management
Due to the unique non-cytotoxic action used by super-oxidised solutions, Microdacyn is one of the only antimicrobial solution technologies indicated for even the most delicate human anatomy including; cartilage, CNS tissue and the peritoneum
This makes Microdacyn an ideal surgical irrigation as well as topical technology
Microdacyn = 0.004% HOCl Super-oxidised solution
OCT = Octenidine dihydrochloride
PMHB = Polyhexanide
PVP-I - Povidone-Ioidne
Infection, the most important complication relating to a wounds ability to heal.
Forming the foundation for Microdacyn's superior wound management is a technology that is clinically proven as a more potent antimicrobial when compared to powerful clinical standards such as 10% Povidone Iodine
Not only is Microdacyn less toxic to the wound but its more potent as an antimicrobial
Microdacyn was compared to Betadine in a randomized control trial measuring SSI (surgical site infection) rates.
178 patients undergoing coronary artery bypass grafting (CABG) were randomly selected to receive either Microdacyn or Betadine treatment for the surgical sites where the sternal wires were placed during cardiothoracic surgery
The Microdacyn group incurred nearly half the superficial infections than that of the Betadine group (5.7% Vs 11.1% respectively)
These superficial infections were managed with routine wound care and antibiotics
The Microdacyn group incurred no deep tissue infections compared to the 4 patients (4.4%) in the Betadine group that required surgical intervention and extended hospital resources to resolve
Abdul Mohd et al - Microdacyn Irrigation in Reducing Infection of a Median sternotomy Wound
The Heart Surgery Forum 13(4) 2010 DOI: 10.1532/HSF98.20091162
Many of the highly oxidising components that give Microdacyn is super-oxidising abilities are the same as those produced and consumed within our natural oxygen-dependent immune response. Principally hypochlorous acid (HOCl).
Oxygen is a crucial component of all life on earth and without it, no healing could occur.
Choosing a technology that utilises similar oxygen-derived molecules to those produced by the immune system may help us leverage the multiple roles they play in timely wound healing.
The use of Microdacyn in wounds such as diabetic and venous ulcers has demonstrated a rapid elevation in tcpO2 (transcutaneous oxygen pressure) for up to 72 hours per application
Right - Non-Insulin Dependent Diabetics (NIDDM) Cohort tcpO2 measures graphed from the below table (n=393)
Below - A table extract from a paper titled "Effects of Microdacyn Solution on Venous Leg Ulcers (VLU): Experience With 1249 VLUs in 897 Patients"
IDDM: Insulin Dependent Diabetes Mellitus, NIDDM: Noninsulin Dependent Diabetes Mellitus, BMI: Body Mass Index, PAD: Peripheral Artery Disease (Ankle/Brachial systolic pressure index <0.80), MDRI: Multidrug resistant infection
Cheryl M. Bongiovanni, - PhD, RVT, CWS, FASA, FACCWS
Journal of the American College of Clinical Wound Specialists (2016) 6, 32–7
The latest clinical practice guidelines published by the international wound infection institute cite super-oxidized hypochlorous acid (Microdacyn) with the ability to "penetrate biofilms rapidly, killing formations from within"
Further research inlcuding some of what is listed below confirm the onset of this action in minutes
More research by Johani et al in 2017 discovered that only three of their test products were able to effect a statistically significant reduction of both gram negative and gram positive biofilms at 15 minutes;
As the literature for Microdacyn's efficacy in improved wound healing continues to grow the case for superiority is becoming somewhat irrefutable. With antibiotic resistance continuing to rise at an alarming rate the need to adopt these modern technologies is now!
If you're looking to adopt an evidence-based care model that improves healing and betters infection control outcomes then its time to make the switch to Microdacyn Wound Care